HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Southam, C. M. Articles by Siegel, A. H. Search for Related Content PubMed PubMed Citation Articles by Southam, C. M. Articles by Siegel, A. H.

Serum Levels of Second Component of Complement in Cancer Patients¹

From the Sloan-Kettering Institute for Cancer Research and Memorial and James Ewing Hospitals, New York, New York

Abstract

The levels of the second component of complement (C'2) in the serum of cancer patients were determined. The average of C'2 titers in the cancer group was slightly higher than in the healthy control group but the differences were not statistically significant. Among patients with lymphosarcoma and reticulum cell sarcoma, a few had very low C'2 levels, and all patients with Hodgkin's disease and multiple myeloma had moderately high levels. The biologic significance of these differences is obscure. They are not explained by such variables as technique, sex, age or therapy. Impending death was often, but not consistently, associated with low C'2 levels. In a small group of patients with various non-neoplastic diseases the only abnormality of note was a very low C'2 titer in a patient with lupus erythematosus.

Footnotes

¹ These studies were supported in part by grants from the American Cancer Society (T 229) and the National Cancer Institute, United States Public Health Service (CY 3215 and CA 08748).